Response to Bayer by Chapman, Louisa
Macalester International
Volume 11 The Body: Meditations on Global Health Article 19
Summer 2002
Response to Bayer
Louisa Chapman
Follow this and additional works at: http://digitalcommons.macalester.edu/macintl
This Response is brought to you for free and open access by the Institute for Global Citizenship at DigitalCommons@Macalester College. It has been
accepted for inclusion in Macalester International by an authorized administrator of DigitalCommons@Macalester College. For more information,
please contact scholarpub@macalester.edu.
Recommended Citation
Chapman, Louisa (2002) "Response to Bayer," Macalester International: Vol. 11, Article 19.
Available at: http://digitalcommons.macalester.edu/macintl/vol11/iss1/19
Response
Louisa E. Chapman*
It is an honor to be invited to again participate in the intellectual life of
the Macalester campus, and to respond to the thoughts of Dr. Bayer.
Multiple interesting and significant themes wind through the sun-
light and shadows of Dr. Bayer’s essay. The six that most captured my
imagination can be capsulized as follows: 1) Confronting illusions of
safety; 2) The human propensity for scapegoating in response to fear;
3) The value of worthy adversaries; 4) The difficulty of framing the
right questions; 5) The complexity of allocating finite resources in a
world of infinite need; and 6) Tensions between our responsibilities to
the patients of today and of tomorrow.
*****
Dr. Bayer begins his portrait by describing the pre-AIDS perception
that the advent of the antibiotic era had consigned infectious disease
epidemics to history. He ends it by concluding: “The notion of a
plague, like the great Bubonic plague of the European Middle Ages, is
no longer a metaphor. It is real and it is harsh.” This initial summation
reflected an underestimation of the power of microbes and an overesti-
mation of the power of modern medical science.
Science is a process of promulgating and testing hypotheses. A pri-
mary hypothesis around which our current thinking in biological sci-
ences is organized is the concept of evolution, and of evolutionary
change in response to environmental pressure. When worlds are sepa-
rate and barrier-protected, the ecosystems within them attain a sort of
homeostasis. When the barriers are removed and new pressures are
introduced, previously stable worlds grow unstable. One way in
which they manifest that instability is through the emergence and
reemergence of infectious diseases.
Mechanisms of evolutionary adaptation are inherent in both infec-
tious agents and their natural hosts. The disease-producing potential
of an infection is a function of the relation between the host and the
infecting agent; the biologic features of both are contributory. Thus, the
pathogenic potential of an infection can change in an unpredictable
fashion when the infecting microbe is transmitted from a host, with
which it has co-evolved for millennia, into a different host.
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This phenomenon is observed repeatedly in zoonotic diseases. A
zoonosis is a disease that is transmitted from one animal species into
another. Each of five hantaviruses recognized as causing zoonotic dis-
ease in humans is associated with a distinct rodent host. The phyloge-
netic relation among the viruses mirrors that among their rodent hosts,
indicating that they have evolved together. In the rodent hosts, the
hantaviruses produce no detectable morbidity or mortality. When the
viruses cross species lines into humans, however, they cause disease
with mortality rates as high as 50 percent.
Other zoonotic examples are easy to find. In the macaque monkey,
its natural host, Cercopithecine herpesvirus 1 (B virus) has a clinical
profile very similar to that of herpes simplex infection in humans.
However, B virus infection in other primates, including humans,
results in an encephalitis for which the mortality rate is about 70 per-
cent. The infection of rhesus monkeys with human measles virus
results in mild disease similar to that in humans, but in marmoset
monkeys such infection produces severe, frequently fatal disease.
“Microbes don’t carry passports” is a common shorthand used to
acknowledge that in the modern era of globalization no human sub-
population can expect protection from infection introduced into
humans anywhere in the world. Compelling data argue that the
human AIDS pandemic began as a zoonotic disease. The human
immunodeficiency virus type 2 (HIV-2) epidemic in West Africa began
with the transmission of Simian immunodeficiency virus (SIV) from a
sooty mangabey monkey into a human, with subsequent transmission
among humans. In central Africa, the cross-species transmission of SIV
from a different primate species, the chimpanzee, appears to have
resulted in the HIV-1 pandemic. Initial infections of humans in Africa
before 1970 resulted in more than a decade of insidious human-to-
human transmission before AIDS was first identified as a public health
problem in the United States in 1981. By the advent of the twenty-first
century, it had transformed from a geographically circumscribed
zoonotic infection into an endemic human infection of pandemic pro-
portions.
When geographic distance provided a more significant barrier to
human interactions, increases in virulence were repeatedly seen when
infections that had long been endemic in certain human subpopula-
tions gained initial access to other, previously isolated, human sub-
populations. During the century that followed Christopher
Columbus’s trans-Atlantic passage in 1492, the European mind per-
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ceived the universe to consist of two worlds: the so-called “Old
World,” defined by Europe and its adjacent land masses, and the so-
called “New World” that had awaited discovery on the other side of
the vast barrier of the Atlantic ocean. As the residents of these two
worlds increasingly intermingled, many things changed. The explorers
brought with them Old World microbes such as measles and smallpox.
These viruses were scourges with which the Europeans had coexisted
and co-evolved for millennia. Processes of natural selection had
repeatedly resulted in adaptation by both the microbes and the human
hosts. On the human side, the biologically most resistant Europeans
were the ones most likely to survive infection and contribute to the
gene pool of subsequent generations. The immunity to reinfection
acquired by individual survivors within each generation collectively
resulted in a “herd immunity” that minimized the size and disruptive
impact of subsequent outbreaks on society as a whole. When these Old
World microbes were introduced into New World human populations
with whom they had not co-evolved, and among whom no herd
immunity existed, the initial impact was devastating.
This microbial exchange was not unilateral. The human residents of
the New World had also spent millennia co-evolving with their own
endemic microbes. During the sixteenth century, a new epidemic dis-
ease referred to as “The Great Pox” ravaged Europe and Asia, impact-
ing societies in major ways and resulting in countless deaths. We can
never know the origin of this devastating illness with certainty. How-
ever, some medical historians believe that it was a virulent manifesta-
tion of venereal syphilis, transported from the New World to the Old
World by Columbus’s fellow explorers. The comparatively mild
nature of modern day syphilis may reflect a change in the virulence of
the spirochete or an evolutionary adaptation of the human hosts.
This theory is controversial. Other historians believe that syphilis
began as a nonvenereal zoonotic infection introduced from nonhuman
animals into humans in Asia or Europe, and that it was the advent of
urbanization that allowed it to grow to pandemic proportions. What-
ever its origin, syphilis continued to rank as one of the great medical
scourges of mankind from its first recognition in the 1490s until the
advent of penicillin in the last century.
A differential vulnerability of human populations to specific infec-
tions has been repeatedly observed in association with human migra-
tions. When Britons departed England to serve as colonial governors
in Sierra Leone, West Africa, their average life expectancy dropped to
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about six months. The rapidity with which colonial governors suc-
cumbed to tropical infections earned colonial Sierra Leone the sobri-
quet “The White Man’s Grave.” Europeans who came to the
southeastern coast of colonial America as indentured servants also
encountered tropical infections, such as malaria and yellow fever, with
which they had no prior experience. Fewer than one in seven survived
the seven-year term of indentureship, making indentured Europeans a
poor economic bargain compared to humans enslaved on the west
coast of Africa and transported to labor contemporaneously in the
same fields. Africans had a survival advantage conferred by preexist-
ing immunity to these diseases. An infectious disease rewriting the
course of history is not a unique occurrence.
Dr. Bayer described initial hopes that the availability of the first
antiretroviral drug, AZT, would radically alter the life expectancy of
those living with AIDS, and the subsequent dashing of those hopes.
The identification of HIV as the cause of AIDS was followed by an
announcement from then-Secretary Heckler of substantial financial
support for biomedical research with the goal of producing a vaccine
within five years. Nearly two decades later, we are still pursuing that
goal, with humbled expectations. Is it necessary to have a vaccine that
is fully protective or would even a partially effective vaccine be of con-
siderable value? That question was unthinkable in 1985. HIV is not the
only threat to human health for which our vaccine development efforts
have thus far failed. Further, the pace at which microbes, including
HIV, are developing resistance to existing antimicrobials is a major
concern among infectious disease professionals.
The Department of Defense has rarely underestimated the power of
microbes. Historically, more soldiers have died from infections than
from bullets. Products of research funded by the military include the
first antibiotics, sulfa drugs and penicillin; a shifting pharmacopeia
that produces new treatments as malaria grows increasingly resistant
to older remedies; multiple vaccines, including tetanus, rabies, and
yellow fever; and much more. As a result, increases in the probability
that a child born in the developing world will survive to adulthood
may owe more to military research and development than to any other
single funding source. U.S. Army research has also contributed much
to our understanding of the fundamental biology of HIV. In 2001, Jef-
frey Sachs, a developmental economist at Harvard, argued that the
provision of AIDS treatment in the developing world was absolutely
necessary to preserve the social fabric of societies with high levels of
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infection. The CIA had recognized this more than a decade earlier
when they identified AIDS as one of the most significant strategic
threats to world stability. Ministries of Health worldwide are relatively
poor and powerless arms of government. To seriously impact an issue
through intergovernmental coalitions, you must move it onto the
agendas of the ministries where money and power reside. The destabi-
lizing impact of AIDS in the developing world has been an issue on
Department of State briefing documents for both the previous Secre-
tary of State, Madeline Albright, and the current one, Colin Powell.
*****
Scapegoating is a very common human response to pain or fear. And
scapegoating is a recurring motif in Dr. Bayer’s essay.
A. Scapegoating the Diseased: Are Homosexuals the Problem?
The early perception of a “Gay epidemic” had a compelling power
to make the majority of humankind feel safer. This bias contributed
both to significant delays in recognizing the world transforming
potential of this pandemic, and to delays in implementing preventive
efforts directed toward the numerically largest vulnerable population,
heterosexuals. AIDS in the developing world has always been an over-
whelmingly heterosexual disease.
B. Scapegoating the Unfamiliar: Are Aliens the Problem?
The ports of entry into the U.S. were rapidly closed to HIV-infected
immigrants. This policy negligibly impacted the prevalence of HIV
infection within the U.S., but perhaps had some impact on health care
costs.
C. Scapegoating the Givers of Incomplete Hope: Are Drug Compa-
nies the Problem?
Drug companies produced and marketed AZT and other causes for
hope. Patent rights ensure profits to the manufacturers of therapeutic
products. Profits ensure the stability of the companies and the capabil-
ity and incentive to fund new research, offering hope of new cures in
the future. If releasing patent rights also decreases the capital available
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to support future research and development, it becomes necessary to
ask if we are abandoning our responsibility to the patients of the future
in response to the agony of the patients of today.
Are pharmaceutical companies and patent rights selfish, profit-dri-
ven evils? Or are they additional scapegoats in a complex world where
the most painful thing to accept is our own impotence in the face of
injustice, vulnerability, disease, and death?
D. Scapegoating Moral Relativism: Is an Absence of Firm Principle
the Problem?
Impassioned statements about the treacherous embrace of moral
relativism, the failure of moral understanding implicit in inadequate
appreciation of context, and the immorality of rigid application of
moral principles pervade arguments about what constitutes ethical
research on human subjects in the developing world.
It is always easier to work with black and white than to struggle
with shades of gray. Rigidity provides a certain sense of safety. But
safety carries its own price. Does our allegiance to principles empower
or abandon our commitment to the human souls those principles were
intended to protect? Does a refusal to bend on principle constitute a
triumph of moral will or a failure of moral courage?
*****
About the ethical debates that surrounded the use of the placebo,
Bayer observes, “What made the encounters so intense and furious is
that they pitted against each other those who saw themselves as
deeply committed to the protection of the vulnerable.”
The value of a worthy ally is always obvious. But when the desired
outcome is the public good rather than the triumph of the individual
will, a worthy adversary who pushes you to examine your reasoning
and question your assumptions may be more valuable than any ally.
*****
Is the existence of any therapy the appropriate standard against which
the ethics of using a placebo should be weighed? Or is the existence of
a therapy that is available to the community of concern? Does an
acceptance of ethical relativism open a door allowing exploitation of
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vulnerable populations for research? Or does a refusal to pursue
research that requires us to wrestle with moral shades of gray ignore
the pressing needs of vulnerable people for the sake of the philosophi-
cal comfort of the ethicist?
Were quarantine and other time-honored tools of infection control
inappropriate public health responses to AIDS because the nature of
the infected was different — or because the nature of the infection was
different?
Are drug trials experiments on human subjects or opportunities for
health care?
Study of the scientific method teaches us to formulate hypotheses,
and then to examine the truth of these hypotheses. The study of philos-
ophy teaches us to maintain vigilance for the begged question. Initial
assumptions in both scientific and ethical reasoning are essentially a
form of hypothesis, and we should begin by questioning them.
Whether the issue at hand is the appropriate use of the placebo in
research, the allocation of fiscal resources, or the best public health pol-
icy response, the first imperative is to frame the most pertinent ques-
tions. When rigorous ethical reasoning based on standard assumptions
leads to outcomes that seem to conflict with or ignore the needs of the
people most at risk, it is time to reassess whether you are in fact fram-
ing the right questions.
*****
Framing the availability of antiretroviral drugs to the developing
world solely in terms of the moral obligation of the wealthiest nations
to the poorest is too simple. Moral obligation cannot be discussed
meaningfully in a context that fails to acknowledge the complexity of
allocating finite resources in a world of infinite need. Very real limita-
tions place a gulf between desire and ability. In real life, the question is
never “how do we fix it all?” It is always “what is the best use of the
resources we have at our disposal today, given that they are absolutely
inadequate to address the evident need?”
A. Left in the Shadows: the Disenfranchised among Us
Bayer describes the emergence of two worlds of AIDS: one where
AIDS is treatable and another where AIDS equals death. These worlds
are not defined by the geopolitical boundaries that separate the devel-
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oped and the developing worlds. Very real inequalities exist within
developed nations. The disenfranchised are not just “over there.” They
dwell with little hope in many pockets of America.
*****
Implicit in much of Bayer’s discussion was a tension between our
responsibility to the patients of today and our responsibility to the
patients of tomorrow. Was the concept that “drug trials are treatment,
too” an empowering benefit to the patients of today or an artifice that
offered only the illusion of benefit at the cost of delaying the availabil-
ity of effective treatment for future patients? When placebo-controlled
trial restrictions were loosened, were we responding with reason and
compassion to the needs of the vulnerable or were we retreating to an
illusion of power in the face of overwhelming powerlessness?
Alteration of the standard approach to drug evaluation through
strict placebo control trials — with the intent of opening access to
experimental therapy to all who might benefit from it — resulted in
both gains and losses. The scientific method is the basis of the power
that enables a transformation from medicine that comforts to medicine
that cures. Placebo-control trials are not designed either to protect the
vulnerable, or to treat the ill. Rather, when current medicine has noth-
ing of proven benefit to offer the patients of today, randomized
placebo-control trials are designed to maximize the efficiency with
which we meet our responsibilities to the patients of the future.
Shortcutting the randomized placebo-control trial under the argu-
ment that all patients deserve access to potentially beneficial therapies
is problematic in two ways: (1) it assumes efficacy of experimental
approaches while failing to acknowledge fully the potential to do
harm, and (2) it undercuts the efficiency with which the efficacy and
safety of experimental approaches can be defined.
Triage is a hardheaded necessity on the battlefield and in medicine.
The conclusion of the debates about the ethics of developing world tri-
als was that placebo use was crucial to policymakers required to make
costly decisions under conditions marked by profound poverty and
scarce public health resources. This press for efficiency was driven by
an economy of lives, not just an economy of dollars.
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